3056-13-1

Usage

Uses

Used in Nucleic Acid Research:
1-(2-deoxy-3,5-di-p-toluoyl-β-L-ribose)-5-methyluracil is used as a modified nucleoside analog for its potential role in the study and manipulation of nucleic acids. Its unique structure allows for specific interactions and modifications that can be beneficial in understanding the behavior and function of nucleic acids.
Used in Drug Development:
In the pharmaceutical industry, 1-(2-deoxy-3,5-di-p-toluoyl-β-L-ribose)-5-methyluracil is used as a chemical building block for the development of new drugs. Its structure can be incorporated into drug candidates to target specific biological pathways or to improve the pharmacological properties of existing drugs.
Used in Biochemical Studies:
1-(2-deoxy-3,5-di-p-toluoyl-β-L-ribose)-5-methyluracil is used as a substrate for enzymatic reactions in biochemical research. Its modified structure can provide insights into the mechanisms of enzymatic processes and help in the discovery of new enzymes or the optimization of existing ones for various applications.
Overall, 1-(2-deoxy-3,5-di-p-toluoyl-β-L-ribose)-5-methyluracil is a versatile and specialized chemical compound with potential applications in various scientific and medical fields, including nucleic acid research, drug development, and biochemical studies.

Upstream product

• 3056-13-1 3',5'-di-O-p-toluoyl-2'-deoxythymidine 
• 65-71-4 thymin 
• 141846-57-3 3,5-di-O-(4-methylbenzoyl)-2-deoxy-α-L-erythro-pentofuranosyl chloride 
• 3056-12-0 3,5-Di-O-p-toluoyl-2-desoxy-L-ribofuranosylchlorid 
• 446251-73-6 (2S,3R)-2-(hydroxymethyl)-5-methoxytetrahydrofuran-3-ol 
• 29780-54-9 (4R,5S)-5-(hydroxymethyl)tetrahydrofuran-2,4-diol 
• 100-02-7 4-nitro-phenol 
• 7288-28-0 2,4-bis(trimethylsiloxy)-5-methylpyrimidine 

Downstream Products

• 3056-13-1 3',5'-di-O-p-toluoyl-α-2'-deoxythymidine 
• 4449-43-8 α-deoxythymidine 
• 50-89-5 C₁₀H₁₄N₂O₅ 

Relevant academic research and scientific papers

4 - Thiodeoxythymidine derivative and anti-hepatitis B virus pharmaceutical application thereof

4 - Thio-deoxythymidine derivatives and anti-hepatitis B virus pharmaceutical applications thereof are disclosed. The invention provides 4 - thiodeoxythymidine derivative or a pharmaceutically acceptable salt thereof, and the structure is shown in structural formula I or structural formula II. An in-vitro cytotoxicity test and an in-vitro anti HBV virus pharmacodynamic test proves 4 - thiodeoxythymidine derivative or a pharmaceutically acceptable salt thereof has anti HBV activity, has an anti-hepatitis B drug development prospect and provides a potential choice for treating viral hepatitis.

Method for preparing high-purity telbivudine compound

The invention belongs to the technical field of medicine and provides a method for preparing a high-purity telbivudine compound. The method includes the steps that an LTD-4 compound serves as the raw material and reacts with thymine subjected to silicification protection, and an intermediate, namely an LTD-5 compound, can be obtained; then, through deprotection reaction, the telbivudine compound is obtained after post-processing, wherein MeONa serves as an alkaline reagent of the deprotection reaction, and strong-acidity resin serves as a dealkalization reagent. The method simplifies the production process, the yield of each step is high, and a target product high in purity and yield is obtained. Please see the structural formula in the description.

Synthesis of beta-L-2'-deoxy nucleosides

An improved process for the preparation of 2′-modified nucleosides and 2′-deoxy-nucleosides, such as, β-L-2′-deoxy-thymidine (LdT), is provided. In particular, the improved process is directed to the synthesis of a 2′-deoxynucleoside that may utilize different starting materials but that proceeds via a chloro-sugar intermediate or via a 2,2′-anhydro-1-furanosyl-nucleobase intermediate. Where an 2,2′-anhydro-1-furanosyl base intermediate is utilized, a reducing agent, such as Red-Al, and a sequestering agent, such as 15-crown-5 ether, that cause an intramolecular displacement reaction and formation of the desired nucleoside product in good yields are employed. An alternative process of the present invention utilizes a 2,2′-anhydro-1-furanosyl base intermediate without a sequestering agent to afford 2′-deoxynucleosides in good yields. The compounds made according to the present invention may be used as intermediates in the preparation of other nucleoside analogues, or may be used directly as antiviral and/or antineoplastic agents.

Methods of manufacture of 2'-deoxy-beta-L-nucleosides

The present invention relates to the synthesis of 2′-deoxy-β-L-thymidine, 2′-deoxy-β-L-uridine and 2′-deoxy-β-L-cytidine, and their derivatives, such as the 3′-O-acyl or 3′,5′-O-diacyl prodrugs, including the 3′-O-L-aminoacyl and 3′,5′-O-L-diaminoacyl prodrugs, and particularly the 3′-O-L-valinyl and 3′,5′-O-L-divalinyl prodrugs.

OLIGODEOXYRIBONUCLEOTIDES

An oligodeoxynucleotide including an oligonucleotide comprising 5'-phosphates of a nucleoside, formed by combining 2-deoxy-L-erythro-pentose with a nucleic acid base in the form of a β-anomer, linked with each other through 3'→5' phosphodiester linkages;